|
Panelists stressed that people should be tested to make sure theydon't have HIV before starting therapy with Truvada. Patients who already have the virus and begin taking Truvada coulddevelop a resistance to the drug, making their disease even moredifficult to treat. The experts grappled with how to protectpatients while avoiding hurdles that could discourage them fromseeking treatment. "If we put up too many hoops to jump through, there will be peoplewho don't make it through those hoops," said Daniel Raymond, thepanel's patient representative. Truvada first made headlines in 2010, when government researchersshowed it could prevent people from contracting HIV. A three-yearstudy found that daily doses cut the risk of infection in healthygay and bisexual men by 42 per cent, when accompanied by condomsand counseling. Last year another study found that Truvada reducedinfection by 75 per cent in heterosexual couples in which onepartner was infected with HIV and the other was not. Because Truvada is on the market to manage HIV, some doctorsalready prescribe it as a preventive measure. FDA approval wouldallow Gilead Sciences to formally market its drug for that use. False sense of security 'Truvada needs to be taken every day, 100 per cent of the time, andmy experience as a registered nurse tells me that won't happen' Karen Haughey But Truvada's groundbreaking preventive ability has exposed starkdisagreements on prevention among those in the HIV community. WhileTruvada's supporters say the drug is an important new option,critics worry that the drug could give users a false sense ofsecurity, and encourage risky behavior. During the meeting's public comment period, FDA panelists heardfrom more than two dozen doctors, nurses and patients who saidpatients would not take the drug as recommended every day, inaddition to using condoms. "Truvada needs to be taken every day, 100 per cent of the time, andmy experience as a registered nurse tells me that won't happen,"Karen Haughey told the panel. "In my eight years, not one patientthat I've cared for has been 100 per cent adherent." Other speakers worried that wide-scale use of Truvada would divertlimited funding from more cost-effective options. Truvada sells forabout $900 a month, or just under $11,000 per year. The AIDSHealthcare Foundation, which opposes approval of Truvada, estimatesthat 20 HIV-positive patients could be treated for the cost oftreating one patient with preventive Truvada. "Truvada for prevention will squeeze already-constrained healthcare resources that can be better spent on cheaper and moreeffective prevention therapies," the group states in a petition tothe FDA. I am an expert from ferrosiliconalloys.com, while we provides the quality product, such as Magnesium Ferro Silicon , Rare Earth Alloy Manufacturer, Ferro Silicon Barium,and more.
Related Articles -
Magnesium Ferro Silicon, Rare Earth Alloy Manufacturer,
|
